CLINICAL SERVICES OVERVIEW

Size: px

Start display at page:

Download "CLINICAL SERVICES OVERVIEW"

Belinda Lauren Harper
5 years ago
Views:

1 CLINICAL SERVICES OVERVIEW Aizant Drug Research Solutions Pvt. Ltd. Sy. No. 172 & 173, Apparel Park Road, Dulapally, Hyderabad , INDIA. Phone: /91/92: Fax: E. Mail: Web:

2 1.0 Introduction Aizant Drug Research Solutions is a pharmaceutical contract research organization (CRO), which provides integrated drug development solutions with a diverse portfolio of services catering to the pharmaceutical companies globally. Aizant is founded by Dr. Varma Rudraraju, PhD (USA), a pharmaceutical professional with over 25 years of work experience in the USA and five years in India. His last assignment in USA was as Director of Formulation and Development at Hoffmann La Roche. Aizant s core management team comprises professionals with experience in pharmaceutical industries across the world (USA/India/Europe/Australia). Aizant provides end-to-end pharmaceutical development services. The core competencies include Pharmaceutical dosage form development Contract Manufacturing services Stability testing and Microbiology testing services Clinical Development services including Clinical and Bioanalytical Research Aizant offers a diverse portfolio of capabilities partnering with health care companies specializing in new molecular entities (NME s), generics (ANDA s) and over the counter (OTC s) products-globally. 2.0 Clinical Facility Aizant has a fully equipped clinical facility to conduct studies as per regulatory requirements. 80 beds (2 Clinics of 40 bed each) Facility spread in 28,000 Sq. ft. area Dedicated registration area In-house diagnostic laboratory Well equipped ICU s, Bed lift and a ramp with in-house Ambulance IP based cameras to virtually monitor projects Part of Volunteer Cross Participation Verification Scheme (VCPVS) Archival (equipped with CO2 flooding system) Has conducted 600+ clinical studies Customers originate from USA, Europe, Canada, SA, Brazil & India Can handle various dosage forms including solid orals, sub-linguals, orally disintegrating tablets, parenterals, pessaries and suppositories

3 3.0 Bioanalytical Facility Aizant s bioanalytical facility has 10 LC-MS/MS including a state of art high end API 5500 where method sensitivity required Facility spread in 7,000 Sq. ft. area More than 250 validated methods Capable to deal with complex methods such as Paricalcitol, Ursodiol, Ethinyl Estradiol, Nicotin Excellent tie-up with animal facilities to offer one stop solution for preclinical needs Range of equipment and instruments to support sample processing 4.0 Regulatory Approvals S. NO. REGULATORY AGENCY INSPECTION DATE(S) INSPECTION AREA OUTCOME 1. DCG(I) 17 APR 2008 FACILITY INSPECTION 2. DCG(I) 3. USFDA 4. NABL (ISO 15189:2007) 22 MAR 2010 AND 23 MAR 2010 (RENEWAL AUDIT) FACILITY INSPECTION 12 APR 2010 TO 16 APR 2010 CLINICAL PHASE OF STUDY 08 MAY 2010 AND 09 MAY 2010 DIAGNOSTIC FACILITY 5. ANVISA 12 JUL 2010 TO 16 JUL 2010 FACILITY INSPECTION 6. WHO 20 OCT 2011 AND 21 OCT TURKEY (MOH) NABL (ISO 15189:2007) CLINICAL PHASE OF STUDY 20 DEC 2011 AND 21 DEC 2011 FACILITY INSPECTION 03 MAR 2012 AND 04 MAR 2012 (RENEWAL AUDIT) DIAGNOSTIC FACILITY 9. ISO 9001: DEC 2012 TO 12 DEC 2012 FACILITY INSPECTION 10. USFDA 10 JUN 2013 TO 14 JUN 2013 (SECOND AUDIT) 11. ANSM (FRANCE) 07 OCT 2013 TO 09 OCT ISO 9001: NABL (ISO 15189:2012) 14. DCG(I) 15. ISO 9001: NOV 2013 (SURVEILLANCE AUDIT) 05 APR 2014 AND 06 APR 2014 (RENEWAL AUDIT) 02 JUN 2014 AND 03 JUN 2014 (RENEWAL AUDIT) 26 DEC 2014 (SECOND SURVEILLANCE AUDIT) ALL PHASES OF STUDY CLINICAL PHASE OF STUDY FACILITY INSPECTION DIAGNOSTIC FACILITY FACILITY INSPECTION FACILITY INSPECTION 16. ANVISA 25 FEB 2015 TO 27 FEB 2015 ALL PHASES OF STUDY 17. WHO 23 MAR 2015 TO 25 MAR 2015 ALL PHASES OF STUDY

4 18. UK-MHRA 26 OCT 2015 TO 30 OCT ISO 9001: USFDA 21. USFDA 28 JAN2016 AND 29 JAN 2016 (RECERTIFICATION AUDIT) 16 AUG 2016 TO 26 AUG 2016 (THIRD AUDIT) 17 OCT 2016 TO 21 OCT 2016 (SECOND AUDIT) 5.0 Clinical Development Services FACILITIES (GCP/GLP) INSPECTION AND ALL PHASES OF THE SELECTED STUDIES FACILITY INSPECTION CLINICAL PHASE OF STUDY BIO-ANALYTICAL PHASE OF STUDY Aizant offers following clinical services: Bioavailability & Bioequivalence Studies Steady State Pharmacokinetics & Pharmacodynamics Studies Patient PK Studies Clinical End-Point Studies Method Development and Validations for New chemical entities Bioanalysis of samples Biostatistics (Phoenix & SAS) Clinical study monitoring Studies in Special Population (geriatric, postmenopausal etc) Vaccine Studies Therapeutic Peptides and Protein Analysis

5 6.0 List of Validated Methods Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Abacavir + Lamivudine Abacavir * + Lamivudine * (Very high Sensitive) Abacavir * + Lamivudine * (Extended Linearity) Human Plasma K2 EDTA & K3 EDTA Premier XE Human Plasma K3 EDTA API-4000 Human Plasma K3 EDTA API ng/ml 6000 ng/ml 10 ng/ml 2400 ng/ml 5 ng/ml 4000 ng/ml 2.5 ng/ml 2000 ng/ml 50 ng/ml ng/ml 20 ng/ml 6000 ng/ml Abiraterone * 0.2 ng/ml ng/ml Acomprosate * Human Plasma K2 EDTA API ng/ml 1000 ng/ml Aceclofenac Human Plasma K2 EDTA API µg/ml - 50µg/mL Acetazolamide * 60 ng/ml ng/ml Albuterol * Human Plasma K2 EDTA Premier XE 0.1 ng/ml 30 ng/ml Amoxicillin + Clavulanic Acid $ 66 ng/ml ng/ml 40 ng/ml ng/ml Apixaban * Human Plasma K2 EDTA API ng/ml ng/ml Aprepitant Human Plasma K2 EDTA Premier XE 10 ng/ml 5000 ng/ml Armodafinil* Human Plasma K2 EDTA API ng/ml ng/ml Artemether & Dihydroartemisinin Aspirin* + Salicylic Acid *$ Atorvastatin* + o-hydroxy Atorvastatin* + p-hydroxy Atorvastatin* Human Plasma K3 EDTA API ng/ml 500 ng/ml Human Plasma Sod. Fluoride API ng/ml 4050 ng/ml 80 ng/ml ng/ml 200 pg/ml pg/ml 200 pg/ml pg/ml 200 pg/ml pg/ml Azelnidipine + Olmesartan * 1 ng/ml 40 ng/ml & 3.0 ng/ml 1200 ng/ml Bupropion 1.5 ng/ml 500 ng/ml Bupropion* ng/ml 500 ng/ml Hydroxy Bupropion 10 ng/ml 3000 ng/ml

6 Bupropion* + Hydroxy Bupropion + Erythro Bupropion* + Threo Bupropion* 1 ng/ml 600 ng/ml 2.5 ng/ml 1500 ng/ml 2 ng/ml 1200 ng/ml 2 ng/ml 1200 ng/ml Cefixime 20 ng/ml ng/ml Cefpodoxime * Human Plasma K2 EDTA Premier XE 40 ng/ml 8000 ng/ml Celecoxib * Human Plasma K2 EDTA Premier XE 10 ng/ml 3000 ng/ml Celecoxib * Human Plasma K2 EDTA Premier XE 5 ng/ml 3000 ng/ml Choline Fenofibrate (as Fenofibric acid)* Carbamazepine + Oxcarbamazepine + 10-Hydroxy Oxcarbazepine Human Plasma K2 EDTA Premier XE 80 ng/ml ng/ml Human Plasma K2 EDTA Premier XE 12 ng/ml 6000 ng/ml 10 ng/ml 5000 ng/ml 25 ng/ml ng/ml Cilostazole Human Plasma K2 EDTA Premier XE 5 ng/ml 2000 ng/ml Cinacalcet * Human Plasma K2 EDTA Premier XE 02 ng/ml 80 ng/ml Clarithromycin Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Clarithromycin + 14-Hydroxy Clarithromycin Human Plasma K2 EDTA & K3 EDTA Premier XE 10 ng/ml 4000 ng/ml 5 ng/ml ng/ml Clobazam * 1 ng/ml 1000 ng/ml Clonazepam * Human Plasma K2 EDTA API pg/ml pg/ml Clopidogrel * Human Plasma K2 EDTA Premier XE 0.1 ng/ml 6000 ng/ml Cycloserine * 200 ng/ml 40000ng/mL Dapsone * Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Deferasirox Human Plasma K2 & K3 EDTA API µg/mL 50µg/mL Des loratidine + 3-OH-Des loratidine * Desogestrel* $ (as 3-Keto desogestrel) 50 pg/ml pg/ml for both Human Plasma K2 EDTA API pg/ml 10 ng/ml Dexamethasone * Human Plasma K2 EDTA API ng/mL to 80 ng/ml Diclofenac Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Dienogest $ 1 ng/ml 200 ng/ml Dienogest (Sensitive Method) * $ 0.8 ng/ml 200ng/mL Diltiazem Human Plasma K2 EDTA Premier XE 1 ng/ml 700 ng/ml Diltiazem Human Plasma K2 EDTA Premier XE 0.6 ng/ml 600 ng/ml

7 N-Desmethyldiltiazem Desacetyldiltiazem * 0.3 ng/ml 300 ng/ml 0.3ng/mL 300 ng/ml Dipyridamole * Human Plasma K2 EDTA Premier XE 20 ng/ml ng/ml Doxicycline Human Plasma K2 EDTA Premier XE 10 ng/ml 2000 ng/ml Drospirenone * $ Human Plasma K2 EDTA Premier XE 1 ng/ml 200 ng/ml Efavirenz * Human Plasma K2 EDTA Premier XE 60 ng/ml ng/ml Entacavir * Human Plasma K2 EDTA API pg/ml pg/ml Eplerenone * 10 ng/ml 6000 ng/ml Eslicarbazepine * Human Plasma K3 EDTA API ng/ml ng/ml Esomeprazole Human Plasma K2 EDTA API ng/ml 6440 ng/ml Ethinyl Estradiol* $ 5 pg/ml 500 pg/ml Ethinyl Estradiol* $ (Sensitive) 3 pg/ml 600 pg/ml Etodolac * 0.2 µg/ml - 80 µg/ml Everolimus ng/ml 100 ng/ml Exemestane * $ 0.1 ng/ml 40 ng/ml Ezetimib + Ezetimibe phenoxy β-d-glucuronide * $ 0.1 ng/ml 20 ng/ml & 1 ng/ml 200 ng/ml Febuxostat * Human Plasma K2 EDTA Premier XE 25 ng/ml 7000 ng/ml Felbamate * Human Plasma K2 EDTA API µg/mL 80µg/mL Felodipine * 0.2 ng/ml 20 ng/ml Fenofibric acid * Human Plasma K2 EDTA Premier XE 80 ng/ml ng/ml Fingolimod * $ Whole Blood K2 EDTA API pg/ml 5000 pg/ml Fosamprenavir (as Amprenavir)* Fosamprenavir (as Amprenavir)* Sensitive method Human Plasma K2 EDTA Premier XE 40 ng/ml 16 µg/ml Human Plasma K2 EDTA Premier XE 20 ng/ml 10 µg/ml Gabapentin 20 ng/ml 15 µg /ml Gestodene Human Plasma K2 EDTA API pg/ml 6200 pg/ml Gliclazide * Human Plasma K2 EDTA Premier XE 20 ng/ml 6000 ng/ml Gliclazide * Human Plasma K3 EDTA API ng/ml 6000 ng/ml Glipzide * Human Plasma K2 EDTA API ng/ml 1500 ng/ml Glimepride * 3 ng/ml 1500 ng/ml Hydroxazine * Human Plasma K2 EDTA API ng/ml 150 ng/ml

8 Ibuprofen* Human Plasma K2 EDTA Premier XE 0.2 µg/ml 120 µg/ml Isoniazide * Human Plasma K3 EDTA API ng/mL ng/ml Irbesartan * 10 ng/ml ng/ml Ketoconazole * 50ng/mL 8000 ng/ml Lamivudine Human Plasma K2 EDTA Premier XE 25 ng/ml 5000 ng/ml Lansoprazole Human Plasma K2 EDTA Premier XE 5 ng/ml 5000 ng/ml Lacosamide * Human Plasma K2 EDTA Premier XE 75 ng/ml ng/ml Levodopa Carbidopa * 5 ng/ml 3000 ng/ml 1 ng/ml 600 ng/ml Levocitirizine 1 ng/ml 600 ng/ml Levonorgestrel * $ 100 ng/ml 3500 ng/ml Linezolide * Human Plasma K2 EDTA API µg/ml 50 µg/ml Lopinavir + Ritonavir * Human Plasma K3 EDTA Premier XE 40 ng/ml ng/ml & 2 ng/ml 600 ng/ml Lumefantrine * Human Plasma K3 EDTA Premier XE 0.1 µg/ml 20 µg/ml Mesalamine * 25 ng/ml 3000 ng/ml Meloxicam 5 ng/ml ng/ml Metoprolol* 0.2 ng/ml 200 ng/ml & K3 EDTA Metoprolol Human Plasma K2 EDTA Premier XE 1.5 ng/ml 535 ng/ml Metaxalone * Human Plasma K2 EDTA Premier XE 20 ng/ml ng/ml Metformin + Gliclazide * Human Plasma K2 EDTA Premier XE 20 ng/ml ng/ml Methocabomol Human Plasma K2 EDTA Premier XE Methocabomol * 100 ng/ml ng/ml 100 ng/ml ng/ml Modafinil * 50 ng/ml ng/ml Mono Methyl Fumarate * $ Human Plasma K2 EDTA API ng/ml 4000 ng/ml Mono Methyl Fumarate * $ (Short Run Time) Human Plasma K2 EDTA API ng/ml 4000 ng/ml Montelukast * Human Plasma K2 EDTA Premier XE 1 ng/ml 1000 ng/ml Moxifloxacin * Human Plasma K2 EDTA Premier XE 30 ng/ml 6000 ng/ml Naproxen * Human Plasma K2 EDTA Premier XE 1 µg/ml 200 µg/ml Nicotine * $ Human Plasma K2 EDTA API ng/ml 30 ng/ml Nifedipine Human Plasma K2 EDTA Premier XE 500 ng/ml ng/ml Nitrofurantoin * Human Plasma K2 EDTA API ng/ml 2000 ng/ml

9 Nitrofurantoin (Sensitive)* Human Plasma K2 EDTA API ng/ml 1500 ng/ml Norethindrone * $ Human Plasma K2 EDTA API pg/ml Norgestrel $ Human Plasma K2 EDTA & K3 EDTA API pg/ml 50 ng/ml Olmesartan * 10 ng/ml 4000 ng/ml Olmesartan* + Amlodipine* 5 ng/ml 2200 ng/ml 50 pg/ml pg/ml Omeprazole Human Plasma K2 EDTA Premier XE 5 ng/ml 4000 ng/ ml Ondansetron * 200 pg/ml 100 ng/ml Pantoprazole Human Plasma K2 EDTA API ng/ml 7500 ng/ml Paricalcitol* $ Human Plasma K2 EDTA API pg/ml 1000 pg/ml Paricalcitol* $ Rat Plasma K2 EDTA API pg/ml pg/ml Paroxetine 200 pg/ml pg/ml Penciclovir Human Plasma K2 EDTA API ng/ml 5000 ng/ml Pitavastatin + Pitavastatin Lactone* 500 pg/ml 400 ng/ml 500 pg/ml 400 ng/ml Posaconazole * Human Plasma K3 EDTA API ng/ml 2200 ng/ml Prazequatel * Human Plasma K2 EDTA API ng/ml 2500 ng/ml Prednisolone * Human Plasma K2 EDTA Premier XE 3 ng/ml 1050 ng/ml Propranolol+ 4-Hydroxy Propranolol * $ Human Plasma K2 EDTA Premier XE Propafenone * $ + 5-Hydoxy Propafenone* Prothionamide* + Prothionamide Sulphoxide Human Plasma K3 EDTA Premier XE 1.5 ng/ml 700 ng/ml 1.2 ng/ml 550 ng/ml 1 ng/ml 500 ng/ml 1 ng/ml 500 ng/ml 30ng/mL 4000ng/mL + 50ng/mL 6600ng/mL Pyridostigmine $ 0.5 ng/ml 125 ng/ml Quetiapine * Human Plasma K2 EDTA Premier XE 1 ng/ml 1500 ng/ml Ranolazine * Human Plasma K2 EDTA Premier XE 5 ng/ml 4000 ng/ml Rasagiline * 30 pg/ml pg/ml Rosuvastatin * 0.2 ng/ml 200 ng/ml Risedronic Acid * $ Human Plasma K2 EDTA API pg/ml pg/ml Risedronic Acid Extended Linearity * $ ng/ml 500 ng/ml Rivaroxaban * Human Plasma K2 EDTA API ng/ml 430 ng/ml

10 Rivaroxaban Extended Linearity * 1 ng/ml 600 ng/ml Rizatriptan * 0.2 ng/ml 80 ng/ml Scenidazole Human Plasma K2 EDTA Premier XE 0.2 µg/ml 40 µg/ml Sertraline 0.5 ng/ml 100 ng/ml Simvastatin + Simvastatin Acid * $ Human Plasma K2 EDTA API ng/ml 100 ng/ml (For both) Sirolimus Human Whole Blood K2 EDTA API ng/ml 100 ng/ml Sulphomathoxazole + Trimethoprime Human Plasma K3 EDTA API µg/mL 120µg/mL + 30 ng/ml ng/ml Tadalafil * Human Plasma K2 EDTA Premier XE 0.2 ng/ml 1000 ng/ml Tenofovir * + Emtricitabine * Human Plasma K2 EDTA Premier XE 8 ng/ml 2000 ng/ml 16 ng/ml 4000 ng/ml Tacrolimus Human Whole Blood Telmisartan* + HCTZ* K2 EDTA Premier XE 0.5 ng/ml 100 ng/ml 1.0 ng/l 150 ng/ml 1.0 ng/ml 1200 ng/ml Teriflunamide * Human Plasma K2 EDTA API ng/ml 4000 ng/ml Tolterodine * Human Plasma K2 EDTA Premier XE 10 pg/ml 3500 pg/ml Tolterodine +5 OH Tolterodine *$ Trandalopril *+ Trandaloprilate * 30 pg/ml to pg/ml 0.2 ng/ml 80 ng/ml ng/ml 120 ng/ml Tranylcypromine * $ 0.7 ng/ml 140 ng/ml Urapidil Human Plasma K2 EDTA Premier XE 5 ng/ml 1500 ng/ml Ursodeoxycholic acid Glycodeoxycholic acid Human Plasma Na. Heparin API-4000 Taurodeoxycholic acid * $ 10 ng/ml 9060 ng/ml 10 ng/ml 9300 ng/ml 5 ng/ml 300 ng/ml Valproic acid Human Plasma K2 EDTA API µg/ml 150 µg/ml Valsartan * Human Plasma K2 EDTA Premier XE 50 ng/ml ng/ml Valsartan + HCTZ * 30 ng/ml ng/ml 1 ng/ml 500 ng/ml Verapamil * + Nor Verapamil * 1.5 ng/ml 600 ng/ml for both

11 Zileuton * Human Plasma K2 EDTA Premier XE 50 ng/ml ng/ml Ziprasidone * Human Plasma K2 EDTA Premier XE 1 ng/ml 200 ng/ml *: Labeled Internal Standard; $: Premium method

12 7.0 List of Methods Ready for Validation Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Agomelatine Human Plasma K3 EDTA API ng/ml 25 ng/ml Aripiprazole Human Plasma K3 EDTA PREMIER XE ng/ml 100 ng/ml Atazanavir + Ritonavir Human Plasma K3 EDTA API ng/ml 8000 ng/ml &5 ng/ml 4000 ng/ml Bromocriptine Human Plasma K2 EDTA API pg/ml 500 pg/ml Cefdinir 30 ng/ml 9000 ng/ml Canagliflozin Human Plasma K3 EDTA API ng/ml 7500 ng/ml Dabigatran 1 ng/ml 500 ng/ml Darunavir + Cobicistat Human Plasma K3 EDTA API ng/ml ng/ml + 20ng/mL 2000ng/mL Deslansoprazole Human Plasma K2 EDTA Premier XE 10 ng/ml 400 ng/ml Dolutegravir Human Plasma K3 EDTA API ng/ml 7000 ng/ml Drospirenone Sensitive 0.5 ng/ml 100 ng/ml Total Dabigatran 1 ng/ml 500 ng/ml Efavirenz (Sensitive) Human Plasma K3 EDTA Premier XE 5.0 ng/ml 1500 ng/ml Ethinyl Estradiol (Sensitive) Fingolimod Phosphate Human Plasma K2 EDTA API pg/ml 200pg/mL Human Whole Blood K2 EDTA API pg/ml 5000 pg/ml Ivacaftor Dog Plasma K2 EDTA API ng/ml 8000 ng/ml Lamivudine + Stavudine Human Plasma K2 EDTA Premier XE 25 ng/ml 5010 ng/ml Lamotrigine 1 ng/ml to 750 ng/ml Lopinavor + Ritonovir 1 ng/ml to (Sensitive Method) 0.1 ng/ml to 60ng/mL Meclizine Human Plasma K2 EDTA Premier XE 0.5 ng/ml 300 ng/ml Medroxy Progesterone Human Plasma K2 EDTA API pg/ml pg/ml Mesalamine (Extended Linearity) Human Plasma K3 EDTA API ng/ml 3000 ng/ml Metformin Human Plasma K2 EDTA Premier XE 10 ng/ml 4000 ng/ml Omeprazole (without buffer) cis-phytonadion & trans-phytonadion Human Plasma K3 EDTA Premier XE 5 ng/ml 4000 ng/ml Human Plasma K3 EDTA API ng/ml to 100 ng/ml

13 Name of the Compound Matrix Anti-Coagulant Equipment Linearity Range Pramipexole 20 pg/ml 4000 pg/ml Rabeprazole Human Plasma K2 EDTA Premier XE 3 ng/ml 1500 ng/ml Raltegravir Human Plasma K3 EDTA Premier XE 15 ng/ml ng/ml Ritonavir Human Plasma K2 EDTA Premier XE 10 ng/ml 2000 ng/ml Ritonavir (Sensitive) Human Plasma K3 EDTA API ng/ml 5000 ng/ml Testosterone Dog Serum N/A API ng/ml 500 ng/ml Tenofovir (Sensitive) + Emtricitabine Human Plasma K3 EDTA API ng/ml 250 ng/ml 20 ng/ml 2500 ng/ml Thiotropium Human Plasma K2 EDTA API pg/ml 500 pg/ml Traimcinolone Dog Plasma K2 EDTA API pg/ml 5000 pg/ml

14 8.0 List of Method Under Development Name of the Compound Matrix Anti-Coagulant Amlodipine + Irbesartan Human Plasma K2 EDTA Anagrelide Human Plasma K2 EDTA Atazanavir + Ritonavir Human Plasma K3 EDTA Aripiprazole Human Plasma K2 EDTA Azelnidipine + Olmesartan Human Plasma K2 EDTA Apremilast Rat Plasma K2 EDTA Asenapine Human Plasma K2 EDTA Azathioprine Human Plasma K2 EDTA Cefuroxime Human Plasma K2 EDTA Clopidogrel + Clopidogrel Acid Human Plasma K2 EDTA Cobicistat + Elvitegravir Human Plasma K3 EDTA Dalfampridine Human Plasma K2 EDTA Dapoxetine Human Plasma K2 EDTA Desmopressin Human Plasma K2 EDTA Dolutegravir + Darunavir + Ritonavir Human Plasma K3 EDTA Dutasteride Human Plasma K2 EDTA Elitriptan Human Plasma K2 EDTA Empagliflozin Human Plasma K2 EDTA Enalapril + Enalaprilate Human Plasma K2 EDTA Entacapone Human Plasma K2 EDTA Estradiol Human Plasma K2 EDTA Fingolimod Phosphate Human Whole Blood K2 EDTA Fludrocortisone Human Plasma K2 EDTA Hydrocortisone Human Plasma K2 EDTA Lacidipine Human Plasma K2 EDTA Levomefolate Human Plasma K2 EDTA Levothyronine (T3) Human Plasma K2 EDTA Linagliptin Human Plasma K2 EDTA Lopinavir + Ritonavir (Sensitive Method) Human Plasma K3 EDTA Methyl Prednisolone Human Plasma K2 EDTA Nadalol Human Plasma K2 EDTA Prasugrel Human Plasma K2 EDTA Pristinamycin I &II Human Plasma K2 EDTA Sofosbuvir Human Plasma K3 EDTA Tamsulosin Human Plasma K2 EDTA Tenofovir Alfenamide Human Plasma K3 EDTA

15 Name of the Compound Matrix Anti-Coagulant Amlodipine + Irbesartan Human Plasma K2 EDTA Valgancyclovir + Gancyclovir Human Plasma K2 EDTA

Innovative Products Available. OTC Products Available

Innovative Products Available. OTC Products Available Innovative Products Benfotiamine film-coated tablets 150 mg Cholecalciferol film-coated tablets 22400 I.U. Diltiazem rectal ointment 2% Agents for Treatment of Hemorrhoids and Fissures Blood and Blood